App-Quantinova.ai

PHYSICIANS’ PRE-LAUNCH AWARENESS AND CONCERNS WITH PIPELINE JANUS KINASE INHIBITORS (JAKIS) VERSUS TOFACITINIB AND BARICITINIB IN RHEUMATOID ARTHRITIS IN THE UNITED STATES AND EUROPE

D. Baldock - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES

S. Johnson - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

PLASMA PROTEOMICS IDENTIFIES A PROTEIN SIGNATURE ASSOCIATED WITH RESPONSE TO RITUXIMAB IN PATIENTS WITH SLE

J. Reynolds - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Rituximab

PLUTO TRIAL OF INTRAVENOUS BELIMUMAB IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (cSLE): PATIENT RESPONSES OVER TIME

N. Ruperto - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

PIM-1 KINASE IS A MEASURABLE MEDIATOR OF CD4+ T CELL DYSREGULATION AND THERAPEUTIC TARGET IN EARLY RHEUMATOID ARTHRITIS

N. Maney - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

PLUTO TRIAL: SENSITIVITY ANALYSES OF SRI4 RESPONSE WITH BELIMUMAB VS PLACEBO IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (CSLE)

N. Ruperto - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Lupus

Belimumab

POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY

D. Courvoisier - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

PREDICTING PATIENTS AT RISK OF FRAGILITY FRACTURE WITH NORMAL BONE MINERAL DENSITY: AN OBSERVATIONAL STUDY

C. Saleh - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

PREDICTING RHEUMATOID ARTHRITIS USING THE SYMPTOMS IN PERSONS AT RISK OF RHEUMATOID ARTHRITIS (SPARRA) QUESTIONNAIRE

L. Van Boheemen - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

PRELIMINARY RESULTS SHOW AN INCREASED EXPRESSION OF COINHIBITORY RECEPTORS IN SYSTEMIC SCLEROSIS

M. Aspari - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

PRELIMINARY DEFINITION OF A POSITIVE MRI FOR STRUCTURAL LESIONS IN THE SACROILIAC JOINTS IN AXIAL SPONDYLOARTHRITIS

W. P. Maksymowych - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

PREVALENCE AND PREDICTORS OF METHOTREXATE-ASSOCIATED ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS

A. Sherbini - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

PREVALENCE AND IMPACT OF COMORBIDITIES IN AXIAL SPONDYLOARTHRITIS: SYSTEMATIC REVIEW AND META-ANALYSIS

S. S. Zhao - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

PREVALENCE OF DISTAL INTERPHALANGEAL JOINT ULTRASONOGRAPHY FEATURES IN PSORIATIC ARTHRITIS, SKIN PSORIASIS, OSTEOARTHRITIS AND HEALTHY INDIVIDUALS: A CROSS-SECTIONAL STUDY

J. Guldberg-Mller - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

PREVALENCE, BURDEN OF DISEASE AND HEALTHCARE UTILIZATION AMONG PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) IN JAPAN 2005-2017

K. E. Sada - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

Prednisone

PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR), CONSENSUS-BASED DEFINITION AND PRELIMINARY VALIDATION.

C. Bruni - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

PRO-INFLAMMATORY DIETS ARE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN AND RHEUMATOID ARTHRITIS IN THE UK BIOBANK COHORT

J. Dainty - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

PROPORTIONS OF PATIENTS ACHIEVING A MINIMAL DISEASE ACTIVITY STATE UPON TREATMENT WITH TILDRAKIZUMAB IN A PSORIATIC ARTHRITIS PHASE 2B STUDY

P. Nash - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Tildrakizumab

PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB AND ADALIMUMAB HEAD TO HEAD IN RA IDENTIFIES NOVEL, DISCRETE EARLY IMMUNE PATHWAY MODULATION IN THE SELECT-COMPARE PHASE 3 STUDY

T. Sornasse - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

ABT-494

PROTEOMIC ANALYSIS REVEALS ASSOCIATION BETWEEN IMMUNE-METABOLIC BIOMARKERS AND CLINICAL SYMPTOMS IN SICCA PATIENTS

V. Pucino - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Sjogren's syndrome

N/A

Filters

45280 Abstracts